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Abstract 
 
Introduction: Co-management of tuberculosis (TB) and HIV is complicated by pharmacologic drug 
interactions between rifampicin (RMP) and certain classes of antiretroviral agents.  The NNRTIs 
Nevirapine (NVP) or Efavirenz (EFV), used to HIV infection, are known to induce the CYP 450 
enzyme system. Thus when RMP is co-administered along with NVP or EFV, the bioavailability of 
RMP could be lowered leading to drug resistance and treatment failure.  
 
Objectives: To study the steady state pharmacokinetics of RMP in HIV and HIV-TB patients 
receiving antiretroviral regimens containing NVP or EFV respectively.  
 
Methods: The study population comprised of HIV and HIV-TB patients undergoing antiretroviral 
treatment with NVP and EFV containing regimens respectively. These patients were also receiving 
concomitant RMP.  Rifampicin was estimated by HPLC in blood collected at different time points 
after drug administration. The pharmacokinetic variables of RMP were calculated using WinNonlin 
software. 
 
Results & Conclusions: Co-administration of NVP or EFV did not alter the pharmacokinetics of 
RMP in HIV and HIV-TB patients, suggesting that the dose of RMP need not be altered during 
antiretroviral treatment with NVP or EFV.   
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Introduction 
 
Tuberculosis (TB) is of particular concern in 
HIV-infected patients, and is the most 
common opportunistic infection observed in 
HIV-infected individuals.  HIV-TB co-infected 
patients merit special considerations 
because co-management of both diseases is 
complicated by potential pharmacologic drug 
interactions between the rifamycins and non-
nucleoside reverse transcriptase inhibitors 
(NNRTIs). 1, 2   
 
Rifampicin (RMP) is an important first line 
anti-TB drug and is usually administered for 
6-8 months along with other drugs for 
treatment of TB. This drug is reported to 
undergo metabolism through the hepatic 
microsomal cytochrome P-450 (CYP 450) 
enzyme system.3   
 
The standard therapy of HIV infection 
consists of 2 NRTIs and 1 NNRTI.  The 
NNRTI could be Nevirapine (NVP) or 
Efavirenz (EFV).  Both these drugs are 
known to induce the CYP 450 enzyme 
system.4,5 Thus when RMP is co-
administered along with NVP or EFV, the 
bioavailability of RMP could be lowered 
leading to drug resistance and treatment 
failure. The best regimens and appropriate 
schedule for the administration of both 
treatments is still not clear.  
 
Lopez et al observed that the 
pharmacokinetics of RMP did not change 
substantially in presence of EFV, even when 
it is administered at elevated doses.6  Ribera 
et al reported that serum RMP levels in 
patients receiving this drug in combination 
with NVP were similar to levels found in 
patients without NVP.7  Their results were 
consistent with that of Robinson et al.8  
Similar information, to the best of our 
knowledge, is lacking in HIV and HIV-TB 
patients in India, who are racially/ethnically 
different. We report the effect of NVP on 
RMP pharmacokinetics in HIV-infected 
patients and that of EFV in HIV-TB patients. 
 
Methods 
 
Patients:  HIV and HIV-TB patients 
attending the outpatient clinic of the 
Government Hospital of Thoracic Medicine, 
Chennai, India, took part in the study.  They 
were required to meet the following inclusion 
criteria: (i) aged 18 – 50 years, (ii) body 
weight not less than 30 kg, (iii) no severe 
hepatic or renal dysfunction (iv) non – 
diabetic, (v) willingness to participate in the 
study and give informed written consent. 
These studies were undertaken after 
obtaining clearance from the Institutional 
Ethics Committee.  Informed written consent 
was obtained from all the patients. 
 
HIV-infected patients were undergoing 
treatment with the fixed-dose combination 
containing NVP (200 mg), lamivudine 
(150mg), and stavudine (30/40 mg).   HIV-TB 
patients were receiving ART regularly with 
EFV (600 mg) along with lamivudine (150 mg 
) and stavudine (30/40 mg ) / zidovudine 300 
mg ) bi-daily. All patients were on ART for 
atleast two weeks prior to the study. Their 
anti-TB treatment consisted of RMP (450/600 
mg), Isoniazid (600 mg), Pyrazinamide (1500 
mg) and Ethambutol (1200 mg) thrice weekly 
for the first 2 months followed by RMP and 
INH thrice weekly according to Revised 
National Tuberculosis Control Program 
regimen (RNTCP). 
 
Conduct of the Study 
 
NVP-RMP study:  Eligible patients were 
instructed to take RMP once daily (450 mg 
 3
for patients weighing less than 60 kg and 600 
mg for those weighing more than 60 kg) for a 
period of 6 days along with their antiretroviral 
regimens, and they were instructed to report 
to the hospital on day 6 for admission into 
the ward.  The pharmacokinetic study was 
conducted on day 7.  On the study day, 
blood samples were drawn in heparinised 
containers predosing and at 1,2,4,6,8 and 12 
hours after administration of antiretroviral 
drugs and RMP, under supervision.   
 
EFV-RMP study: This study was conducted 
after admitting the patients to the hospital.  A 
sample of blood was collected on the study 
day and the EFV and RMP were 
administered under supervision.  Blood 
samples were collected at different time 
points after dosing, similar to the NVP-RMP 
study. 
 
The blood samples were centrifuged and 
plasma stored at -20oC until assay.   
 
Estimation of Plasma RMP 
 
Plasma RMP concentrations were estimated 
by high performance liquid chromatography 
(Shimadzu Corpn., Kyoto, Japan) according 
to a validated method.9 The intra- and inter-
assay variations observed in the plasma 
rifampicin estimations were less than 3.5 % 
and 6.4% respectively.   
 
Pharmacokinetic analysis 
 
Based on the plasma concentrations of RMP 
at different time points, maximum 
concentration (Cmax), and time to attain Cmax 
(Tmax) were determined by visual inspection 
of data.  Other pharmacokinetic parameters 
like t ½, AUC0-12 and Clearance were 
calculated by a non-compartmental model 
using WinNonlin Software, version 5.1 
(Pharsight Corporation., Mountain View, CA).   
 
The pharmacokinetic variables obtained for 
NVP and EFV groups were compared with 
that of the historical controls10 by 
independent t-test (SPSS version 13). 
Results and Discussion 
 
The demographic details of all the patients 
who took part in the study are given in table 
1. The steady state pharmacokinetic 
parameters of RMP when co-administered 
with NVP or EFV are given in table 2.  Data 
reported from one of our earlier studies on 
the pharmacokinetics of RMP when 
administered alone in HIV uninfected TB 
patients is also given in this table for 
comparison.10  The pharmacokinetic 
parameters of RMP of patients receiving this 
drug in combination with NVP or EFV were 
similar to that found in HIV uninfected 
patients.  A test of significance between the 
present study data and that obtained from a 
recently concluded study10 showed that none 
of the pharmacokinetic variables was 
significantly different between the TB 
patients and that of NVP and EFV groups 
 
Our results are consistent with earlier reports 
in which co-administration of RMP along with 
NVP or EFV did not affect RMP plasma 
levels.6-8  This suggests that the 
pharmacokinetics of RMP remains unaltered 
when given along with NVP or EFV despite 
induction of CYP 3A4 by these antiretroviral 
drugs, and that the dose of RMP need not be 
altered during ART. Thus anti-TB treatment 
containing RMP in standard dosages can be 
safely used in combination with ARV regimen 
containing NVP or EFV.  The present 
guidelines recommend the use of EFV when 
the patient is receiving RMP-containing anti-
TB treatment.  Ongoing studies are 
evaluating the safety and efficacy of NVP 
when used along with anti-TB treatment. 
 
 4
Table 1 Demographic detail of patients 
 
Characteristics  HIV  n=13 
HIV-TB 
 n=9 
Sex (No.) Male Females 
9         
4 
7         
 2 
Age (Year) Mean Range 
34     
 28-48 
34 
27-42 
Body weight 
(kg) 
Mean 
Range 
58     
38-91 
47 
34-61 
Height (cm) Mean Range 
161 
145-173 
160 
150-167 
Body Mass 
Index (BMI) 
Mean 
Range 
22.2 
17.8-
33.0 
18.6 
14.3-
22.4 
Duration of 
ATT (Months) 
Mean 
Range - 
3.8 
0.3-6.0 
Duration of 
ART (Months) 
Mean 
Range 
4.5    
 1-8 
3.9 
0.3-14.0 
CD4 counts 
(cells/mm3) 
Mean 
Range 
315   
60-684 
114 
70-199 
 
Table 2 Steady State Pharmacokinetics of 
Rifampicin (450/600 mg) 
 
Mean (range) 
 Cmax 
(µg/ml
) 
Tmax 
(hours
) 
T ½ 
(hours
) 
AUC(0-
12) 
(µg/ml
-hrs) 
CI 
(litres/
min) 
RMP10 
(n = 
13) 
7.2 
(5.5-
8.9) 
2.4 
(1.7-
3.1) 
3.0 
(2.1-
3.9) 
33.0* 
(26.7-
39.4) 
15.0 
(11.8-
18.2) 
With 
NVP 
(n=13) 
8.7  
(5.6-
13.5) 
2.6  
(2.0-
4.0) 
2.1  
(1.4-
3.0) 
43.7  
(28.0-
66.1) 
12.4  
(8.6-
20.9) 
With 
EFV 
(n=9) 
7.7  
(4.8-
11.1) 
2.3 
(1.0-
4.0) 
2.3  
(1.9-
5.1) 
37.8 
(15.0-
53.2) 
12.8  
(8.0-
29.1) 
* denotes AUC 0 to 8 (µg/ml-hrs) 
Cmax- peak concentration; Tmax- time to attain 
C-max; AUC-area under the plasma 
concentration vs. time curve; CI – clearance 
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